BLiNQ Networks Inc., a provider of small cell wireless backhaul services, on Monday announced that it completed two field trials, one with a tier one global mobile operator and another with a fixed access provider in Europe, to test its small cell backhaul services.
According to BLiNQ , the trials, one lasting for 3 weeks and the other for more than a month, produced results corresponding to the expected performance of the system in the defined deployment scenario. The company achieved 70 Mbps in 10 MHz over 330, 400 and 800 meters in non-line-of-sight condition.
The small cell backhaul service tested in the field trials were non-line-of-sight (NLOS), meaning it worked around obstacles to reach small cells deployed below the roofline, says a company spokesperson. The BLiNQ small cell service specifically implements interference management technology (MARA) that coordinates the activities of the backhaul solutions in order to maximize the backhaul capacity.
“The service allows operators to scale deployments of small cells into the hundreds and thousands by using low cost spectrum and reduce planning and deployment costs. Other wireless solutions require lengthy deployment and installation process,” says a BLiNQ spokesperson.
Many small call services use “line-of-sight” (LOS) solutions, which according to BLiNQ, can be time consuming and require two crews at both ends of the link to do the pointing and installation. In NLOS, a single technician at the remote location can point towards the hub module. According to the company, this saves time and money, as no expert technicians are required.
The product is also small in size and weight (3kg, 30x20x8 cm) because it was specially designed to be deployed onto poles. Typical microwave and E-band solutions cost several thousands of dollars to deploy a link. BLiNQ’s solution cuts down the time from two or three hours per installation to less than 15 minutes. The cost of deployment is a fraction of what it is for LOS systems, says the company. This enables mobile operators to deploy many small cells in a short time.
Additional trials in North America and Europe are scheduled in Q2 2012.